Shots:
- The US FDA has granted approval to the company’s Letybo for 50 and 100 units to treat moderate-to-severe glabellar lines in adults
- The approval was based on the data from three P-III completed studies that recruited more than 1,000 participants across the US and the EU
- The data from the clinical studies showed the effectiveness and favorable safety profile of Letybo as a treatment for glabellar lines
Ref: Businesswire | Image: Hugel | Press Release
Related News:- The US FDA Approves Allecra Therapeutics’ Exblifep for the Treatment of Complicated Urinary Tract Infections (cUTIs)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
